289 related articles for article (PubMed ID: 21820552)
1. Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51).
Lepesheva GI; Villalta F; Waterman MR
Adv Parasitol; 2011; 75():65-87. PubMed ID: 21820552
[TBL] [Abstract][Full Text] [Related]
2. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
[TBL] [Abstract][Full Text] [Related]
3. Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.
Hargrove TY; Wawrzak Z; Alexander PW; Chaplin JH; Keenan M; Charman SA; Perez CJ; Waterman MR; Chatelain E; Lepesheva GI
J Biol Chem; 2013 Nov; 288(44):31602-15. PubMed ID: 24047900
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi.
Lepesheva GI; Hargrove TY; Anderson S; Kleshchenko Y; Furtak V; Wawrzak Z; Villalta F; Waterman MR
J Biol Chem; 2010 Aug; 285(33):25582-90. PubMed ID: 20530488
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.
Buckner FS; Bahia MT; Suryadevara PK; White KL; Shackleford DM; Chennamaneni NK; Hulverson MA; Laydbak JU; Chatelain E; Scandale I; Verlinde CL; Charman SA; Lepesheva GI; Gelb MH
Antimicrob Agents Chemother; 2012 Sep; 56(9):4914-21. PubMed ID: 22777048
[TBL] [Abstract][Full Text] [Related]
7. Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.
Hoekstra WJ; Hargrove TY; Wawrzak Z; da Gama Jaen Batista D; da Silva CF; Nefertiti AS; Rachakonda G; Schotzinger RJ; Villalta F; Soeiro Mde N; Lepesheva GI
Antimicrob Agents Chemother; 2016 Feb; 60(2):1058-66. PubMed ID: 26643331
[TBL] [Abstract][Full Text] [Related]
8. Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibition.
Cherkesova TS; Hargrove TY; Vanrell MC; Ges I; Usanov SA; Romano PS; Lepesheva GI
FEBS Lett; 2014 Nov; 588(21):3878-85. PubMed ID: 25217832
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition.
Friggeri L; Hargrove TY; Rachakonda G; Williams AD; Wawrzak Z; Di Santo R; De Vita D; Waterman MR; Tortorella S; Villalta F; Lepesheva GI
J Med Chem; 2014 Aug; 57(15):6704-17. PubMed ID: 25033013
[TBL] [Abstract][Full Text] [Related]
10. Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents.
Suryadevara PK; Racherla KK; Olepu S; Norcross NR; Tatipaka HB; Arif JA; Planer JD; Lepesheva GI; Verlinde CL; Buckner FS; Gelb MH
Bioorg Med Chem Lett; 2013 Dec; 23(23):6492-9. PubMed ID: 24120539
[TBL] [Abstract][Full Text] [Related]
11. Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit.
Chen CK; Doyle PS; Yermalitskaya LV; Mackey ZB; Ang KK; McKerrow JH; Podust LM
PLoS Negl Trop Dis; 2009; 3(2):e372. PubMed ID: 19190730
[TBL] [Abstract][Full Text] [Related]
12. Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.
Chen CK; Leung SS; Guilbert C; Jacobson MP; McKerrow JH; Podust LM
PLoS Negl Trop Dis; 2010 Apr; 4(4):e651. PubMed ID: 20386598
[TBL] [Abstract][Full Text] [Related]
13. Listen to what the animals say: a systematic review and meta-analysis of sterol 14-demethylase inhibitor efficacy for in vivo models of Trypanosoma cruzi infection.
Bisio MMC; Jurado Medina LS; García-Bournissen F; Gulin JEN
Parasitol Res; 2024 Jun; 123(6):248. PubMed ID: 38904688
[TBL] [Abstract][Full Text] [Related]
14. A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
Doyle PS; Chen CK; Johnston JB; Hopkins SD; Leung SS; Jacobson MP; Engel JC; McKerrow JH; Podust LM
Antimicrob Agents Chemother; 2010 Jun; 54(6):2480-8. PubMed ID: 20385875
[TBL] [Abstract][Full Text] [Related]
15. Glutamine metabolism modulates azole susceptibility in
Dumoulin PC; Vollrath J; Tomko SS; Wang JX; Burleigh B
Elife; 2020 Dec; 9():. PubMed ID: 33258448
[TBL] [Abstract][Full Text] [Related]
16. CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase.
Lepesheva GI; Zaitseva NG; Nes WD; Zhou W; Arase M; Liu J; Hill GC; Waterman MR
J Biol Chem; 2006 Feb; 281(6):3577-85. PubMed ID: 16321980
[TBL] [Abstract][Full Text] [Related]
17. Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.
Guedes-da-Silva FH; Batista DDGJ; Da Silva CF; Pavão BP; Batista MM; Moreira OC; Souza LRQ; Britto C; Rachakonda G; Villalta F; Lepesheva GI; Soeiro MNC
ACS Infect Dis; 2019 Mar; 5(3):365-371. PubMed ID: 30625275
[TBL] [Abstract][Full Text] [Related]
18. Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
Riley J; Brand S; Voice M; Caballero I; Calvo D; Read KD
PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004014. PubMed ID: 26394211
[TBL] [Abstract][Full Text] [Related]
19. Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Delta7-24, 25-dihydrolanosterol.
Hargrove TY; Wawrzak Z; Liu J; Waterman MR; Nes WD; Lepesheva GI
J Lipid Res; 2012 Feb; 53(2):311-20. PubMed ID: 22135275
[TBL] [Abstract][Full Text] [Related]
20. Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis.
Lepesheva GI; Waterman MR
Curr Top Med Chem; 2011; 11(16):2060-71. PubMed ID: 21619513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
